对2018年国际妇产联盟宫颈癌新分期的思考

doi:10.3760/cma.j.cn371439-20201230-00123

国际肿瘤学杂志 ›› 2021, Vol. 48 ›› Issue (10): 627-630.doi: 10.3760/cma.j.cn371439-20201230-00123

对2018年国际妇产联盟宫颈癌新分期的思考

牛雯娟¹, 段文杰¹, 苏雅婷¹, 魏芳²()

¹山西医科大学第二临床医学院,太原 030001
²山西医科大学第二临床医院妇科,太原030001

收稿日期:2020-12-30 修回日期:2021-04-27 出版日期:2021-10-08 发布日期:2021-11-24
通讯作者: 魏芳 E-mail:2yuanweifang@163.com
基金资助:
山西省自然科学基金(201901D111363)

Consideration on the new stage of cervical cancer revised by the International Federation of Obstetrics and Gynecology in 2018

Niu Wenjuan¹, Duan Wenjie¹, Su Yating¹, Wei Fang²()

¹Second School of Clinical Medicine, Shanxi Medical University, Taiyuan 030001, China
²Department of Gynecology, Second Clinical Hospital Affiliated to Shanxi Medical University, Taiyuan 030001, China

Received:2020-12-30 Revised:2021-04-27 Online:2021-10-08 Published:2021-11-24
Contact: Wei Fang E-mail:2yuanweifang@163.com
Supported by:
Natural Science Foundation of Shanxi Province of China(201901D111363)

摘要/Abstract

摘要：

一套有效、可靠且实用的分期对宫颈癌的诊治有很大的帮助。宫颈癌是妇科肿瘤中一个采用临床分期的恶性肿瘤,但分期对判断肿瘤大小、宫旁浸润、阴道切缘及脉管浸润等缺乏客观性。2018年10月国际妇产联盟(FIGO)重新修订了之前一直沿用的2009年FIGO宫颈癌分期,但2018年宫颈癌新分期的变更点存在很多争议。

关键词: 宫颈肿瘤, 肿瘤分期

Abstract:

An effective, reliable and practical staging is of great help to the diagnosis and treatment of malignant tumors. Cervical cancer is a malignant tumor using clinical stage in gynecological tumors, but staging lacks objectivity in judging the tumor size, para-uterine invasion, vaginal margin, vascular invasion and so on. By October 2018, the International Federation of Obstetrics and Gynecology (FIGO) had revised the 2009 FIGO cervical cancer staging that had been used before.However, the changed points of the 2018 FIGO cervical cancer staging are controversial.

Key words: Cervical neoplasms, Tumor staging

牛雯娟, 段文杰, 苏雅婷, 魏芳. 对2018年国际妇产联盟宫颈癌新分期的思考[J]. 国际肿瘤学杂志, 2021, 48(10): 627-630.

Niu Wenjuan, Duan Wenjie, Su Yating, Wei Fang. Consideration on the new stage of cervical cancer revised by the International Federation of Obstetrics and Gynecology in 2018[J]. Journal of International Oncology, 2021, 48(10): 627-630.

参考文献 33

[1]	Zhang X, Lv Z, Xu X, et al. Comparison of adenocarcinoma and adenosquamous carcinoma prognoses in Chinese patients with FIGO stageⅠB-ⅡA cervical cancer following radical surgery[J]. BMC Cancer, 2020, 20(1):664. DOI: 10.1186/s12885-020-07148-x. doi: 10.1186/s12885-020-07148-x
[2]	Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6):394-424. DOI: 10.3322/caac.21492. doi: 10.3322/caac.21492
[3]	中华人民共和国国家卫生健康委员会. 宫颈癌诊疗规范(2018年版)[J]. 肿瘤综合治疗电子杂志, 2020, 6(3):33-43. DOI: 10.12151/JMCM.2020.03-06. doi: 10.12151/JMCM.2020.03-06
[4]	Dos Reis R, Andrade CEMC, Frumovitz M, et al. Radical hysterectomy and age: outcomes comparison based on a minimally invasive vs an open approach[J]. J Minim Invasive Gynecol, 2018, 25(7):1224-1230. DOI: 10.1016/j.jmig.2018.03.002. doi: 10.1016/j.jmig.2018.03.002
[5]	Ramirez PT, Frumovitz M, Pareja R, et al. Minimally invasive versus abdominal radical hysterectomy for cervical cancer[J]. N Engl J Med, 2018, 379(20):1895-1904. DOI: 10.1056/NEJMoa1806395. doi: 10.1056/NEJMoa1806395
[6]	许燕萍, 王志启, 梁旭东, 等. 局部晚期子宫颈癌患者腹腔镜与开腹手术的预后比较[J]. 中华妇产科杂志, 2020, 55(9):609-616. DOI: 10.3760/cma.j.cn112141-20200727-00612. doi: 10.3760/cma.j.cn112141-20200727-00612
[7]	Levine MD, Brown J, Crane EK, et al. Outcomes of minimally invasive versus open radical hysterectomy for early stage cervical cancer incorporating 2018 FIGO staging[J]. J Minim Invasive Gynecol, 2020, 28(4):824-828. DOI: 10.1016/j.jmig.2020.07.021. doi: 10.1016/j.jmig.2020.07.021
[8]	Saleh M, Virarkar M, Javadi S, et al. Cervical cancer: 2018 revised International Federation of Gynecology and Obstetrics staging system and the role of imaging[J]. AJR Am J Roentgenol, 2020, 214(5):1182-1195. DOI: 10.2214/AJR.19.21819. doi: 10.2214/AJR.19.21819
[9]	杨东, 张洪文, 刘辉, 等. CT、MRI及正电子发射体层成像CT在宫颈癌诊断中的应用[J]. 国际肿瘤学杂志, 2014, 41(3):220-223. DOI: 10.3760/cma.j.issn.1673-422X.2014.03.019. doi: 10.3760/cma.j.issn.1673-422X.2014.03.019
[10]	Balcacer P, Shergill A, Litkouhi B. MRI of cervical cancer with a surgical perspective: staging, prognostic implications and pitfalls[J]. Abdom Radiol (NY), 2019, 44(7):2557-2571. DOI: 10.1007/s00261-019-01984-7. doi: 10.1007/s00261-019-01984-7
[11]	Merz J, Bossart M, Bamberg F, et al. Revised FIGO staging for cervical cancer-a new role for MRI[J]. Rofo, 2020, 192(10):937-944. DOI: 10.1055/a-1198-5729. doi: 10.1055/a-1198-5729
[12]	Salvo G, Odetto D, Pareja R, et al. Revised 2018 International Federation of Gynecology and Obstetrics (FIGO) cervical cancer staging: a review of gaps and questions that remain[J]. Int J Gynecol Cancer, 2020, 30(6):873-878. DOI: 10.1136/ijgc-2020-001257. doi: 10.1136/ijgc-2020-001257
[13]	Salib MY, Russell JHB, Stewart VR, et al. 2018 FIGO staging classification for cervical cancer: added benefits of imaging[J]. Radiographics, 2020, 40(6):1807-1822. DOI: 10.1148/rg.2020200013. doi: 10.1148/rg.2020200013
[14]	Jung W, Park KR, Lee KJ, et al. Value of imaging study in predicting pelvic lymph node metastases of uterine cervical cancer[J]. Radiat Oncol J, 2017, 35(4):340-348. DOI: 10.3857/roj.2017.00206. doi: 10.3857/roj.2017.00206
[15]	Zhang X, Dong Y, Song Q, et al. The role of multiparametric magnetic resonance imaging in the study of primary tumor and pelvic lymph node metastasis in stage ⅠB1-ⅡA1 cervical cancer[J]. J Comput Assist Tomogr, 2020, 44(5):750-758. DOI: 10.1097/RCT.0000000000001084. doi: 10.1097/RCT.0000000000001084
[16]	Mansoori B, Khatri G, Rivera-Colón G, et al. Multimodality imaging of uterine cervical malignancies[J]. AJR Am J Roentgenol, 2020, 215(2):292-304. DOI: 10.2214/AJR.19.21941. doi: 10.2214/AJR.19.21941
[17]	Haldorsen IS, Lura N, Blaakór J, et al. What is the role of imaging at primary diagnostic work-up in uterine cervical cancer?[J]. Curr Oncol Rep, 2019, 21(9):77. DOI: 10.1007/s11912-019-0824-0. doi: 10.1007/s11912-019-0824-0 pmid: 31359169
[18]	Zyla RE, Gien LT, Vicus D, et al. The prognostic role of horizontal and circumferential tumor extent in cervical cancer: implications for the 2019 FIGO staging system[J]. Gynecol Oncol, 2020, 158(2):266-272. DOI: 10.1016/j.ygyno.2020.05.016. doi: 10.1016/j.ygyno.2020.05.016
[19]	Matsuo K, Machida H, Mandelbaum RS, et al. Validation of the 2018 FIGO cervical cancer staging system[J]. Gynecol Oncol, 2019, 152(1):87-93. DOI: 10.1016/j.ygyno.2018.10.026. doi: S0090-8258(18)31309-X pmid: 30389105
[20]	钟云. FIGO宫颈癌新分期系统的临床探讨[D]. 郑州: 郑州大学, 2020.
[21]	Ayhan A, Aslan K, Bulut AN, et al. Is the revised 2018 FIGO staging system for cervical cancer more prognostic than the 2009 FIGO staging system for women previously staged as ⅠB disease?[J]. Eur J Obstet Gynecol Reprod Biol, 2019, 240:209-214.DOI: 10.1016/j.ejogrb.2019.07.002. doi: S0301-2115(19)30329-X pmid: 31325847
[22]	Fan Y, Wang MY, Mu Y, et al. Ovarian metastasis in women with cervical carcinoma in stages ⅠA to ⅡB: a systematic review and meta-analysis[J]. Medicine (Baltimore), 2020, 99(31):e21146. DOI: 10.1097/MD.0000000000021146. doi: 10.1097/MD.0000000000021146
[23]	Nanthamongkolkul K, Hanprasertpong J. Predictive factors of pelvic lymph node metastasis in early-stage cervical cancer[J]. Oncol Res Treat, 2018, 41(4):194-198. DOI: 10.1159/000485840. doi: 10.1159/000485840 pmid: 29562222
[24]	Pedone Anchora L, Carbone V, Gallotta V, et al. Should the number of metastatic pelvic lymph nodes be integrated into the 2018 Figo staging classification of early stage cervical cancer?[J]. Cancers (Basel), 2020, 12(6):1552. DOI: 10.3390/cancers12061552. doi: 10.3390/cancers12061552
[25]	Li A, Wang L, Jiang Q, et al. Risk stratification based on metastatic pelvic lymph node status in stage ⅢC1p cervical cancer[J]. Cancer Manag Res, 2020, 12:6431-6439. DOI: 10.2147/CMAR.S253522. doi: 10.2147/CMAR.S253522
[26]	Li C, Liu W, Cheng Y. Prognostic significance of metastatic lymph node ratio in squamous cell carcinoma of the cervix[J]. Onco Targets Ther, 2016, 9:3791-3797. DOI: 10.2147/OTT.S97702. doi: 10.2147/OTT.S97702
[27]	Aslan K, Meydanli MM, Oz M, et al. The prognostic value of lymph node ratio in stage ⅢC cervical cancer patients triaged to primary treatment by radical hysterectomy with systematic pelvic and para-aortic lymphadenectomy[J]. J Gynecol Oncol, 2020, 31(1):e1. DOI: 10.3802/jgo.2020.31.e1. doi: 10.3802/jgo.2020.31.e1
[28]	Cibula D, McCluggage WG. Sentinel lymph node (SLN) concept in cervical cancer: current limitations and unanswered questions[J]. Gynecol Oncol, 2019, 152(1):202-207. DOI: 10.1016/j.ygyno.2018.10.007. doi: S0090-8258(18)31286-1 pmid: 30318103
[29]	徐红, 张静. 美国国立综合癌症网络《2020年宫颈癌临床实践指南》病理内容更新解读[J]. 中华病理学杂志, 2021, 50(1):9-13. DOI: 10.3760/cma.j.cn112151-20200712-00548. doi: 10.3760/cma.j.cn112151-20200712-00548
[30]	刘成伟. 验证2018 FIGO宫颈癌新分期系统[D]. 南昌: 南昌大学, 2019.
[31]	Liu X, Wang J, Hu K, et al. Validation of the 2018 FIGO staging system of cervical cancer for stage Ⅲpatients with a cohort from China[J]. Cancer Manag Res, 2020, 12:1405-1410. DOI: 10.2147/CMAR.S239624. doi: 10.2147/CMAR.S239624
[32]	Liu X, Wang W, Hu K, et al. A risk stratification for patients with cervical cancer in stage ⅢC1 of the 2018 FIGO staging system[J]. Sci Rep, 2020, 10(1):362. DOI: 10.1038/s41598-019-57202-3. doi: 10.1038/s41598-019-57202-3
[33]	Grigsby PW, Massad LS, Mutch DG, et al. FIGO 2018 staging criteria for cervical cancer: impact on stage migration and survival[J]. Gynecol Oncol, 2020, 157(3):639-643. DOI: 10.1016/j.ygyno.2020.03.027. doi: S0090-8258(20)30252-3 pmid: 32248993

对2018年国际妇产联盟宫颈癌新分期的思考

Consideration on the new stage of cervical cancer revised by the International Federation of Obstetrics and Gynecology in 2018

RichHTML

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献 33

相关文章 15

编辑推荐

Metrics

本文评价

[1]	张宁宁, 杨哲, 檀丽梅, 李振宁, 王迪, 魏永志. 宫颈细胞DNA倍体分析联合B7-H4和PKCδ对宫颈癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(5): 286-291.
[2]	张露, 蒋华, 林州, 马辰莺, 徐晓婷, 王利利, 周菊英. 免疫检查点抑制剂治疗复发转移性宫颈癌的疗效及预后分析[J]. 国际肿瘤学杂志, 2023, 50(8): 475-483.
[3]	吕璐, 孙鹏飞. 肠道菌群与宫颈癌[J]. 国际肿瘤学杂志, 2023, 50(6): 373-376.
[4]	段传菊, 陈真云, 李晓红, 牛洪朋, 李秀敏. 复发宫颈癌免疫治疗1例[J]. 国际肿瘤学杂志, 2023, 50(12): 766-768.
[5]	马雪艳, 鲁历历, 孙鹏飞. 免疫微环境在宫颈癌中的研究进展[J]. 国际肿瘤学杂志, 2023, 50(1): 47-50.
[6]	张露, 周菊英, 马辰莺, 林州. 复发转移性宫颈癌免疫治疗相关进展[J]. 国际肿瘤学杂志, 2022, 49(9): 517-520.
[7]	史英侠, 胡莉钧, 于静萍. 免疫检查点抑制剂在复发或转移性宫颈癌治疗中的应用[J]. 国际肿瘤学杂志, 2022, 49(9): 568-571.
[8]	彭琛, 谢印通, 张昕, 谢鹏. 宫颈癌维持治疗研究进展[J]. 国际肿瘤学杂志, 2022, 49(7): 430-435.
[9]	熊婵, 阎英, 谢晓冬, 孟繁杰, 于卉影. 辐射诱导的多倍体宫颈癌HeLa细胞生物学特性研究[J]. 国际肿瘤学杂志, 2022, 49(5): 263-269.
[10]	袁晨阳, 周菊英. 宫颈癌预后因素的研究进展[J]. 国际肿瘤学杂志, 2022, 49(5): 307-313.
[11]	袁晨阳, 周菊英, 杜霄, 纪环, 赵天翼. 宫颈癌2018与2009 FIGO分期的比较及预后因素分析[J]. 国际肿瘤学杂志, 2022, 49(3): 151-163.
[12]	王玥, 吴琼, 许愿, 龚唯, 徐晓婷. 老年宫颈癌的筛查与治疗进展[J]. 国际肿瘤学杂志, 2022, 49(12): 754-758.
[13]	陈方明, 蔡园园, 李晗, 王晓丽, 阚红星, 李洋, 郝福荣, 王明臣. 调强放疗鼻咽癌患者UICC第7版与第8版T分期预后差异[J]. 国际肿瘤学杂志, 2021, 48(9): 515-522.
[14]	马秀珍, 卢艳, 赵冰冰, 邱宏聪, 徐勋, 韦敏. 岗松总黄酮对宫颈癌SiHa细胞迁移、侵袭及凋亡的影响[J]. 国际肿瘤学杂志, 2021, 48(4): 206-211.
[15]	于明月, 陈峥峥, 赵旭旭, 任萍萍, 张影, 葛丽, 朱美玲, 赵卫东. 局部晚期宫颈癌术后辅助治疗的影响因素及其列线图风险模型的构建[J]. 国际肿瘤学杂志, 2021, 48(1): 35-40.